Please login to the form below

Not currently logged in
Email:
Password:

Prostrakan and Bayer Schering enter testosterone partnership

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel, Tostran in 65 countries worldwide.

Tostran is a testosterone gel indicated for testosterone replacement therapy in men with hypogonadism, a condition where the testes fail to produce androgen and/or sperm.

Under the terms of the agreement, Bayer Schering will make an undisclosed upfront payment to ProStraken, which will be followed by milestone payments subject to certain approvals and sales targets being met.

Dr Wilson Totten, ProStrakan's chief executive, said: “Outlicensing Tostran to Bayer Schering Pharma in these territories is in line with our strategy of capitalising on the value of our products in parts of the world that are non-core for ProStrakan. In Bayer Schering Pharma, we have a worthy and sizeable partner with a deep understanding of the testosterone replacement market who is well-placed to bring this product to clinicians in each of these territories.”

Tostran is currently marketed in Europe under several brand names including Tostran, Tostrex and Itnogen. The product will be branded Fortigel in the US.

27th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics